Header Logo

Connection

Prudence Kgagudi to Antibodies, Viral

Back to Details
This is a "connection" page, showing publications Prudence Kgagudi has written about Antibodies, Viral.
Prudence Kgagudi
Connection Strength
1,386
Antibodies, Viral
  1. A Global Collaborative Comparison of SARS-CoV-2 Antigenicity Across 15 Laboratories. Viruses. 2024 12 18; 16(12).
    View in: PubMed
    Score: 0,204
  2. Despite delayed kinetics, people living with HIV achieve equivalent antibody function after SARS-CoV-2 infection or vaccination. Front Immunol. 2023; 14:1231276.
    View in: PubMed
    Score: 0,185
  3. Shared N417-Dependent Epitope on the SARS-CoV-2 Omicron, Beta, and Delta Plus Variants. J Virol. 2022 08 10; 96(15):e0055822.
    View in: PubMed
    Score: 0,172
  4. Ultrapotent antibodies against diverse and highly transmissible SARS-CoV-2 variants. Science. 2021 Aug 13; 373(6556).
    View in: PubMed
    Score: 0,160
  5. Therapeutic effect of CT-P59 against SARS-CoV-2 South African variant. Biochem Biophys Res Commun. 2021 08 20; 566:135-140.
    View in: PubMed
    Score: 0,159
  6. Cross-Reactive Neutralizing Antibody Responses Elicited by SARS-CoV-2 501Y.V2 (B.1.351). N Engl J Med. 2021 06 03; 384(22):2161-2163.
    View in: PubMed
    Score: 0,158
  7. Impaired Transplacental Transfer of Respiratory Syncytial Virus-neutralizing Antibodies in Human Immunodeficiency Virus-infected Versus -uninfected Pregnant Women. Clin Infect Dis. 2019 06 18; 69(1):151-154.
    View in: PubMed
    Score: 0,139
  8. Novavax NVX-COV2373 triggers neutralization of Omicron sub-lineages. Sci Rep. 2023 01 21; 13(1):1222.
    View in: PubMed
    Score: 0,045
  9. Emergence and phenotypic characterization of the global SARS-CoV-2 C.1.2 lineage. Nat Commun. 2022 04 08; 13(1):1976.
    View in: PubMed
    Score: 0,042
  10. Escape from recognition of SARS-CoV-2 variant spike epitopes but overall preservation of T cell immunity. Sci Transl Med. 2022 Feb 09; 14(631):eabj6824.
    View in: PubMed
    Score: 0,042
  11. Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 in people living with and without HIV in South Africa: an interim analysis of a randomised, double-blind, placebo-controlled, phase 1B/2A trial. Lancet HIV. 2021 09; 8(9):e568-e580.
    View in: PubMed
    Score: 0,040
  12. SARS-CoV-2 501Y.V2 escapes neutralization by South African COVID-19 donor plasma. Nat Med. 2021 04; 27(4):622-625.
    View in: PubMed
    Score: 0,039
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.